• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oncotelic Therapeutcs Inc (OP:OTLC)

0.0388 +0.0003 (+0.78%)
Streaming Delayed Price Updated: 1:06 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Oncotelic Therapeutcs Inc

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Oncotelic Achieves Breakthrough $1.7 Billion Pipeline Valuation Through GMP Bio Joint Venture
November 20, 2025
Independent valuation reflects major advancement of OT-101 and Deciparticle™ nanomedicine platform 
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Bioscience Publish Landmark Review Defining Sub-15 nm Nanoparticles as New Frontier in Drug Delivery
November 11, 2025
Via Investor Brand Network
Topics Intellectual Property
InvestorNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Venture Begins Clinical Trials of Innovative Cancer Therapy
November 07, 2025
Via Investor Brand Network
Topics Intellectual Property
Sapu Nano Reveals the Initial In-Human Clinical Trial of Sapu-003, Intravenous Everolimus (Afinitor(R)) at Australian Translational Breast Cancer Symposium
November 03, 2025
Via Investor Brand Network
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) to Present Sapu003 Data at 2025 San Antonio Breast Cancer Symposium
October 31, 2025
Via Investor Brand Network
Topics Intellectual Property
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial on Nanomedicine Advances
October 30, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
Oncotelic Therapeutics Inc. (OTCQB: OTLC) at Forefront of Effort to Optimize Next-Generation Cancer Therapies
October 30, 2025
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
October 29, 2025
Via Investor Brand Network
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial on Nanomedicine Innovations in Oncology
October 28, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Working to Transform Underperforming Compounds into Next-Gen Cancer Therapies
October 28, 2025
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
News headline image
Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
October 29, 2025
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NYSE:LLY),(NYSE:JNJ) EQNX::TICKER_END 
Via FinancialNewsMedia
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
October 27, 2025
Via Investor Brand Network
News headline image
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
October 27, 2025
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOBT),(NYSE:NVS),(NASDAQ:BCAX),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Announces Three Accepted Abstracts on Deciparticle (TM) Everolimus (Sapu003) at 2025 San Antonio Breast Cancer Symposium
October 23, 2025
Via Investor Brand Network
Topics Intellectual Property
Nanomedicine’s Next Leap: Why Particle Size Matters in Cancer Drug Delivery
October 21, 2025
Via Investor Brand Network
NetworkNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Positioned to Fill Critical Gaps in Cancer Care with RNA and Small-Molecule Therapies
October 17, 2025
Via Investor Brand Network
Topics Intellectual Property
Oncotelic Therapeutics Inc.’s (OTLC) Sapu003: Injectable Everolimus (Afinitor(R)) to Begin Clinical Trials, Aiming to Boost Drug Bioavailability
October 08, 2025
Via Investor Brand Network
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Announces Phase 1 Trial of Sapu-003, a Novel Intravenous Deciparticle(TM) Everolimus, Now Open for Enrollment in Australia
October 08, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
Sapu Nano Unveils First-in-Human Clinical Trial of Sapu-003 at 8th Australian Translational Breast Cancer Research Symposium
October 08, 2025
Using Sapu Nano’s proprietary Deciparticle™ technology, Sapu-003 delivers everolimus intravenously 
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Oncotelic Therapeutics Inc. (OTLC) Venture Sapu Nano Receives Approval to Begin Human Clinical Trials of Sapu003, an Injectible Form of Afinitor(R) (Everolimus) for Breast Cancer Treatment
October 01, 2025
Via Investor Brand Network
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Joint Venture Sapu Nano Receives Approval to Begin Phase 1 Trial of Injectable Everolimus for Breast Cancer
September 24, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
Sapu Nano’s Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients
September 24, 2025
Sapu003 Designed to Overcome Limitations of Afinitor®, FDA-Approved Oral Everolimus, by Delivering Full Strength of the Drug via Intravenous Injection 
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) CEO Featured on IBN’s BioMedWire Podcast
September 22, 2025
Via Investor Brand Network
Topics Intellectual Property
Oncotelic Therapeutics Inc. (OTLC): Leadership and Innovation Drive Late-Stage Biotech Momentum
September 19, 2025
Via Investor Brand Network
Topics Intellectual Property
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsAudio Release on Innovative Therapeutics Pipeline
September 19, 2025
Via Investor Brand Network
Topics Intellectual Property
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial on Advancing Cancer Research
September 18, 2025
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Creating Pioneering Pipeline Designed to Transform Cancer, Rare Diseases Treatments
September 18, 2025
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Advancing Cancer Research Brings New Hope for Patients Worldwide
September 17, 2025
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Oncotelic Therapeutics Inc. (OTLC) Champions Targeted RNA Therapy for Underserved Cancers
September 17, 2025
Via Investor Brand Network
Topics Death
News headline image
Advancing Cancer Research Brings New Hope for Patients Worldwide
September 17, 2025
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NASDAQ:AZN),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence Intellectual Property
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap